MedPageToday -- Long-acting injectable risperidone (Risperdal Consta) was no more successful than oral antipsychotics in keeping patients with schizophrenia or schizoaffective disorder out of the hospital, a randomized trial found. The rate of hospitalization among patients receiving the long-acting agent was 39% after a mean of 10.8 months, compared with a rate of 45% after 11.3 months among those being treated with oral antipsychotics (HR 0.87, 95% CI 0.63 to 1.20), according to Robert A. Rosenheck, MD, of Yale University, and colleagues.
